| Blueprint Medicines is a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy. Co. has one precision therapy approved by the United States Food and Drug Administration, and is developing investigational medicines in clinical development, along with various research programs including: Avapritinib, which is for the treatment of systemic mastocytosis (SM); BLU-263, which is for the treatment of indolent SM and other mast cell disorders; pralsetinib, which is for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors; and fisogatinib, which is for the treatment of hepatocellular carcinoma. We show 24 historical shares outstanding datapoints in our BPMC shares outstanding history coverage, used to compute BPMC market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BPMC market cap history over the course of time is important for investors
interested in comparing BPMC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BPMC versus a peer is one thing; comparing
BPMC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BPMC can fluctuate over the course of history.
With this page we aim to empower investors researching BPMC by allowing them to research the BPMC market cap history.